Market research
SVRA Savara Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 951M
- P/E ratio
- Not available
- Analyst target
- 11.0556
- Dividend yield
- Not available
- Beta
- 0.2
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 951M
- P/E ratio
- Not available
- Analyst target
- 11.0556
- Dividend yield
- Not available
- Beta
- 0.2
About
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Research context
Savara Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SVRA discussion.
5 years, 6 months ago
Savara Inc is currently in a long term downtrend where the price is trading 3.2% below its 200 day moving average.
From a valuation standpoint, the stock is 60.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 528.5.
Savara Inc's total revenue rose by inf% to $1K since the same quarter in the previous year.
Its net income has increased by 56.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow fell by 23.6% to $-12M since the same quarter in the previous year.
Based on the above factors, Savara Inc gets an overall score of 3/5.